• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Varenicline safe for smoking cessation in patients with stable major depressive disorder

bys25qthea
September 17, 2013
in Chronic Disease, Psychiatry, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. In smokers with stable or past major depressive disorder (MDD), varenicline improved rates of smoking abstinence compared to placebo after 12 weeks of treatment and through an additional 40 weeks of follow-up. 

2. Despite concerns regarding its neuropsychiatric safety profile, this study suggests that in this patient population varenicline is not associated with increased exacerbations of mood or anxiety symptoms during treatment or follow up periods.   

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Smoking and depression are among the leading causes of disability and death worldwide; they are also commonly comorbid.  Although varenicline has been shown to be effective in improving smoking abstinence rates compared to both placebo and bupropion, studies to date have excluded smokers with preexisting psychiatric disorders due to concerns about its neuropsychiatric safety profile.  This study is the first randomized controlled trial to investigate the use of varenicline in patients with stable or past MDD.  The results of this study demonstrates a significantly increased rate of smoking abstinence compared to placebo after 12 weeks of treatment and after 40 weeks post-treatment.  Furthermore, the study showed no clinical difference in standardized measurements of mood and anxiety between the treatment and placebo group during the study period.  These results are largely consistent with prior data suggesting that smokers with comorbid stable MDD would benefit from varenicline without risk of exacerbation of psychiatric symptoms.  The major limitation of this study is that they excluded patients with untreated or active depression, as well as patients with other frequently associated psychiatric conditions such as psychosis or mania.

Click to read the study, published today in the Annals of Internal Medicine

Relevant Reading: Nicotine receptor partial agonists for smoking cessation

RELATED REPORTS

Age-related macular degeneration may be associated with depression risk

The Scan by 2 Minute Medicine®: The Fight Against Childhood Obesity, Prioritizing Mental Health, The Rise of XBB1.5, and Choose Your Chocolates Wisely

Physical activity may be helpful in treating depressive symptoms in children and adolescents

In-Depth [randomized, double-blinded, placebo controlled study]: This multicenter study randomized 525 patients to receive either varenicline (titrated to 1 mg twice daily over the course of the first week) or placebo.  Eligible patients smoked at least 10 cigarettes per day, exhaled carbon monoxide greater than 10 ppm, were motivated to stop smoking, and met DSM criteria for unipolar MDD without psychosis, either successfully treated within two years or currently treated with an antidepressant at a stable dose.  Patients were excluded for psychosis, mania, or severe personality disorders, as well as for non-psychiatric disorders such as severe COPD, cardiovascular disease, cancer, or any other severe, acute, or unstable illness.  Patients were followed during two weeks of treatment and then followed for another 40 weeks.  The primary outcome was continuous abstinence rate (CAR) from weeks 9-12 as measured by exhaled carbon monoxide.  CAR from weeks 9-24 and 9-52 were recorded as secondary outcomes.  Rates of abstinence were compared with a 2-group, continuity-corrected, chi-square test.

Adverse events, including mood and anxiety disorders as assessed by standardized, validated scales (MADRS for depression and HAM-A for anxiety) were also assessed during treatment and follow-up periods.

Of the 525 patients randomized, 354 completed the study, though all patients were included in final analysis.  Baseline characteristics between the treatment and control groups did not differ significantly.  At weeks 9-12 of treatment, the varenicline group had significantly greater abstinence (OR 3.35, 95% CI 2.16-5.21).  This effect persisted after the treatment period ended, as measured at weeks 9-24 (OR 2.53, 95% CI 1.56-4.10) and weeks 9-52 (OR 2.36, 95% CI 1.40-3.98).  The MADRS and HAM-A scales measured no significant differences in mood or anxiety between treatment and placebo groups throughout the treatment period and up to 4 weeks post-treatment.  C-SSRS scales showed similar rates of suicidal ideation between groups both during and after treatment.  Treatment-emergent adverse events occurred in 72.3% of varenicline subjects and 66.9% of placebo subjects; there were no major differences in rates of adverse events between the treatment and control groups.

By Steven Zhao and Aimee Li MD

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: depressionsmoking
Previous Post

Childhood food allergies associated with significant direct medical costs

Next Post

The EINSTEIN-PE trial: Rivaroxaban to treat pulmonary embolism [Classics Series]

RelatedReports

Antioxidants, omega-3 lack benefit in age-related macular degeneration
Ophthalmology

Age-related macular degeneration may be associated with depression risk

February 6, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Fight Against Childhood Obesity, Prioritizing Mental Health, The Rise of XBB1.5, and Choose Your Chocolates Wisely

January 25, 2023
Certain financial incentive programs may promote increased physical activity
Chronic Disease

Physical activity may be helpful in treating depressive symptoms in children and adolescents

January 18, 2023
Quick Take: Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse
Psychiatry

ECT may be more effective than ketamine in improving depression severity

January 18, 2023
Next Post
Classics Series, Landmark Trials in Medicine

The EINSTEIN-PE trial: Rivaroxaban to treat pulmonary embolism [Classics Series]

Patient transfers to trauma centers often unnecessary

Younger women more likely than men to present with acute coronary syndrome without chest pain

The LACTATE trial: Early lactate-guided therapy in intensive care patients [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Faecal haemoglobin concentrations associated with mortality and cause of death in colorectal cancer screening
  • The Scan by 2 Minute Medicine®: Maternity Leave Left Out, Dry January, A Measles Resurgence, Dr. GPT
  • Former professional football players may be at greater risk of chronic disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options